(Q42756714)

English

Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.

scientific article published on 18 January 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

1 reference

based on heuristic

inferred from title

oligodendrocyte

1 reference

based on heuristic

inferred from title

Pieter Wesseling

7

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

object named as

Ahmed Idbaih

5

0 references

François Ducray

2

object named as

François Ducray

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

author name string

Karima Mokhtari

1

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Johan M Kros

3

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Thierry Gorlia

4

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Martin Taphoorn

6

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Khe Hoang-Xuan

8

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Martin Van den Bent

9

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Marc Sanson

10

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

language of work or name

0 references

publication date

18 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

3014-3026

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

alpha-Internexin expression identifies 1p19q codeleted gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

IDH1 and IDH2 mutations in gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Monoclonal antibody specific for IDH1 R132H mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25827

21 January 2018

Identifiers

10.1002/CNCR.25827

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42756714&oldid=1579269089"